Drug intelligence / Profile preview

BLB-103

Development stage: Preclinical
Lead developer: BayLink Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

BLB-103 is a preclinical-stage therapeutic candidate developed by BayLink Biosciences, targeting Glypican-3 (GPC3). It is designed as a targeted therapy for liver cancer (specifically hepatocellular carcinoma) and lung cancer. The drug functions as a Topoisomerase 1 inhibitor, likely delivered via an antibody-drug conjugate (ADC) modality, which allows for the selective delivery of the cytotoxic payload to GPC3-expressing tumor cells. By inhibiting Topoisomerase 1, BLB-103 prevents DNA religation, leading to lethal DNA strand breaks and apoptosis in malignant cells.

Targets

TOP1 (DNA Topoisomerase I)GPC3 (Glypican-3)

Beyond the preview

Go deeper on BLB-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLB-103.

Explore the full profile